United Therapeutics Corporation $UTHR Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 37.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 5,445 shares of the biotechnology company’s stock after selling 3,242 shares during the period. Cresset Asset Management LLC’s holdings in United Therapeutics were worth $1,565,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Invesco Ltd. boosted its position in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after purchasing an additional 4,145 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in shares of United Therapeutics by 22.5% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock valued at $147,278,000 after purchasing an additional 87,664 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $136,453,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $478.60, for a total value of $10,050,600.00. Following the completion of the transaction, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at $3,896,761.20. The trade was a 72.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $484.23, for a total transaction of $1,936,920.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at $62,949.90. This represents a 96.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 619,300 shares of company stock valued at $277,383,609. Corporate insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $476.36 on Wednesday. The company’s 50 day simple moving average is $455.16 and its 200-day simple moving average is $371.12. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $492.62. The company has a market capitalization of $20.51 billion, a price-to-earnings ratio of 18.05, a price-to-earnings-growth ratio of 4.76 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter last year, the firm earned $6.39 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.